Sei Investments Co. Has $3.36 Million Stake in Xeris Biopharma Holdings, Inc. $XERS

Sei Investments Co. increased its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 45.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 579,210 shares of the company’s stock after acquiring an additional 179,863 shares during the period. Sei Investments Co. owned about 0.34% of Xeris Biopharma worth $3,359,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cetera Investment Advisers grew its position in Xeris Biopharma by 3.9% in the 2nd quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after purchasing an additional 1,735 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Xeris Biopharma by 29.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock worth $63,000 after buying an additional 1,820 shares during the last quarter. Royal Bank of Canada raised its holdings in Xeris Biopharma by 6.5% during the fourth quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock worth $304,000 after buying an additional 2,351 shares during the last quarter. AlphaCentric Advisors LLC lifted its stake in shares of Xeris Biopharma by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 45,886 shares of the company’s stock valued at $266,000 after buying an additional 2,494 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in Xeris Biopharma during the fourth quarter worth $25,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Weiss Ratings upgraded Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Xeris Biopharma presently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Xeris Biopharma Stock Up 7.7%

Shares of NASDAQ:XERS opened at $7.93 on Friday. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $10.08. The company has a market capitalization of $1.37 billion, a PE ratio of -72.09 and a beta of 0.66. The business has a fifty day moving average price of $7.68 and a two-hundred day moving average price of $6.80. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The business had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a positive return on equity of 158.10% and a negative net margin of 5.12%. Analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $8.02, for a total value of $120,300.00. Following the sale, the insider owned 1,676,126 shares of the company’s stock, valued at approximately $13,442,530.52. The trade was a 0.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John Johnson sold 15,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $91,350.00. Following the transaction, the director directly owned 683,083 shares of the company’s stock, valued at $4,159,975.47. This represents a 2.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 266,499 shares of company stock valued at $1,996,417. Company insiders own 4.35% of the company’s stock.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.